Clinical Trials

A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of NivolumabVersus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human EpidermalGrowth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer


Study ID
CA209-7FL

NCT Number
NCT04109066 (Click on the NCT number for more information about the trial)

Research Study Number
2019-0646

Principle Investigator
Dr. Waintraub, Stanley

Phase
III

Sponsor
Bristol-Myers Squibb


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now